All lobbying filings

AVENUE SOLUTIONS

Lobbying for AMGEN, INC. · Biopharmaceutical company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Bills named in this filing 5

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1954
Biosimilar Red Tape Elimination Act
H.R. 10628
Biosimilars Access and Affordability Act
S. 5571
Biosimilars Access and Affordability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.